[{"id":"694735df-ac85-49ba-93fc-bc6caa6ca10b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05868174","created_at":"2023-05-22T16:05:29.186Z","updated_at":"2025-02-25T16:18:49.188Z","phase":"Phase 1","brief_title":"Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors","source_id_and_acronym":"NCT05868174","lead_sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • 177Lu-DOTA-girentuximab (TLX250) • Rencarex (girentuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/23/2023","start_date":" 05/23/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-01"}]